Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head
and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of …

(1) Background: The first line of treatment for recurrent/metastatic Head and Neck Squamous
Cell Carcinoma (HNSCC) has recently evolved with the approval of immunotherapies that …

The anti-epidermal growth factor receptor (EGFR) antibody cetuximab is standard therapy
for head and neck squamous cell carcinoma (HNSCC). However, most HNSCC tumors are …

Purpose: mAbs including cetuximab can induce antibody-dependent cellular cytotoxicity
(ADCC) and cytokine production mediated via innate immune cells with the ability to …

Epidermal growth factor receptor (EGFR) is frequently amplified or overexpressed in head
and neck squamous cell carcinoma (HNSCC) and is a clinically validated target for the …

Background Cumulative evidence implicates the epidermal growth factor receptor (EGFR)
as an important therapeutic target in head and neck squamous cell carcinoma (HNSCC) …

Head and neck cancer is a major cause of morbidity and mortality worldwide. The most
common cancer in the head and neck area is head and neck squamous cell carcinoma …

Background: Anti-EGFR antibody therapy is still one of the clinical choices in head and neck
squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab resistance …

Purpose: Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome
in patients with head and neck cancer (HNC). Cetuximab mediates natural killer (NK) cell …

Results MEHD significantly inhibited proliferation of tumor cells expressing EGFR and HER3
and inhibited phosphorylation of EGFR, HER3 and downstream signaling molecules MAPK …